KemPharm, at work on an abuse-deterrent formulation of hydrocodone, said its lead drug performed well in a study designed to determine how easily the pill can be ground up and snorted.
Eli Lilly is staking its future on a pair of high-stakes Phase III programs, shying away from any big biotech buyouts as sticker prices continue to soar.
Novo Nordisk is jumping on Genmab's antibody development platform in search of two new drug programs--and this time the Danish biotech company will not be focused on another cancer pact.
Avalanche Biotechnologies, months removed from a costly Phase II dud, is calling off plans for further study of its lead gene therapy candidate, heading back to the lab to regroup before trying another clinical trial.
Boehringer Ingelheim is pairing up with a small California biotech to explore the role circuits in the nervous system play in obesity, scouting for drug targets that could spur weight loss.
Boston-based Rhythm has gone back to the venture well to draw up a fresh $40 million in backing from some A-list investors to fuel a mid-stage program for rare genetic disorders linked with a lethal level of obesity.
As the Ebola outbreak continues to wane in West Africa, vaccines experts are combing over what went wrong--and right--with the development of vaccine candidates against the virus.
Senseonics, the maker of an implantable continuous glucose monitor device, has picked up $20 million in venture funding, according to a regulatory filing.
There is no vaccine for respiratory syncytial virus (RSV), which causes 177,000 hospitalizations and 14,000 deaths each year in adults older than 65. But early data from Novavax's Phase II trial of its RSV candidate show its promise in protecting older adults.
A new oncology compound from AbbVie and Roche's Genentech division cleared its primary hurdle in a Phase II blood cancer trial, opening the door to an FDA filing by year's end.